Fragment-based drug discovery (FBDD) is a method for screening and developing small molecules that has gained widespread popularity over the last 25 years in medicinal chemistry. Currently, seven fragment-derived drugs have been approved, and many more are in different clinical stages. In contrast to traditional high-throughput screening, FBDD utilises compounds with fewer atoms, allowing for more efficient coverage of the available chemical space. Additionally, the risk for clashes decreases, facilitating highly efficient interactions with the protein. Fragments, however, usually bind only weakly to their target, necessitating sensitive, biophysical screening methods.